$SRPT CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, announced that it has appointed John C. Martin, Ph.D., to its Board of Directors, effective today. Dr. Martin brings decades of executive leadership to Sarepta’s board, having played an instrumental role in building one of the world’s foremost biotechnology companies. During his 20-year tenure as chief executive officer of Gilead Sciences, he oversaw the growth of the company and development of its scientific portfolio into 24 marketed products. “John’s business record is unparalleled, and he brings expertise and insight gleaned from leading the long-term, transformational growth of one of the industry’s premier companies that will add to the strength of the Sarepta board. We are incredibly fortunate to welcome him to the company’s board of directors,” said M. Kathleen Behrens, Ph.D., Chairperson of Sarepta’s Board of Directors. “Having introduced curative therapies, John’s vision, acumen, and wisdom are unique in our industry. As Sarepta prepares to deliver one-time therapies for rare diseases, John’s strategic guidance as a member of the company’s board will be invaluable as we work to change the model for how rare diseases are treated,” said Doug Ingram, Sarepta’s president and chief executive officer. И чего она падает на этой новости? Вроде же хорошая новость.